The France-based biotechnology company bioMérieux has invested in Swiss start-up Plair to accelerate adoption of real‑time environmental monitoring in pharmaceutical cleanrooms.
The move focuses on Plair’s RAPID‑C+ platform, which combines continuous viable particle counting with standard total particle measurement, giving quality teams immediate microbial insights.
“Our investment in Plair is a strategic step forward in our ambition to be the partner of choice for advancing pharmaceutical quality control,” said Michael Reynier, Senior Vice President of Pharma Quality Control at bioMérieux.
As part of the collaboration, Reynier will join Plair’s board, reinforcing the operational and strategic alignment between the two companies.
Plair also collaborated with the science and technology company Merck last year to expand the geographical reach of the real-time viable particle monitoring solution, Rapid-C+, in over 100 countries.
bioMérieux says the investment complements its existing pharmaceutical quality control portfolio and augments its environmental monitoring offerings, a key area of focus as manufacturing compliance and data integrity needs evolve globally.
Pharmaceutical manufacturers are increasingly seeking technologies that cut manual sampling and give continuous visibility into cleanroom air quality to ensure product safety and compliance.
Plair says the collaboration could help expand regulatory acceptance of real‑time viable particle counting, providing manufacturers with actionable data to maintain aseptic standards and improve cleanroom oversight.
